Drug intelligence / Profile preview

RADA16

Development stage
Unknown
Lead developer
3-D Matrix
Modality
Peptides
Administration
Topical
01

Overview

RADA16 nanopeptide gel, marketed under the brand name PuraStat, is a fully synthetic self-assembling peptide (SAP) hydrogel developed by 3D-Matrix. The active ingredient is a 16-amino acid polypeptide (Ac-RADARADARADARADA-NH2) composed of four naturally occurring amino acids repeated four times. In its acidic formulation, RADA16 exists as a viscous solution; however, upon contact with physiological fluids such as blood (neutral/alkaline pH), the peptides spontaneously self-assemble into beta-sheet nanofibers that rapidly crosslink into a stable, transparent 3D hydrogel matrix. This matrix mimics the native extracellular matrix and acts as a mechanical barrier to provide rapid haemostasis and support mucosal wound healing. It is primarily used as a topical haemostatic agent in various surgical procedures, including endoscopic nasal surgery and gastrointestinal endoscopy, to control bleeding and prevent postoperative complications such as adhesions (synechiae) and crusting.

Brand names
PuraStat
Other names
RADA16 nanopeptide gelRADA-16 nanopeptide gelRADA 16 nanopeptide gelRADA16 haemostatic gelRADA-16 haemostatic gelRADA 16 haemostatic gelRADA16 hydrogelRADA-16 hydrogelRADA 16 hydrogelRADA16 self-assembling peptideRADA-16 self-assembling peptideRADA 16 self-assembling peptide
02

Targets

LM-332 (Laminin-332)

Beyond the preview

Go deeper on RADA16.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RADA16.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call